ABSTRACT
In this chapter we discuss several important special topics that do not neatly fit into our earlier chapters, but are nonetheless important in the actual practice of Bayesian clinical trials. By necessity, our views reflect our own experience and interest to some extent, but the issues in this chapter do seem to come up fairly regularly, in both in-house studies as well as laterphase trials where working cooperatively with regulatory agencies comes to the fore.
